Serum miR-210 Contributes to Tumor Detection, Stage Prediction and Dynamic Surveillance in Patients with Bladder Cancer

MiR-210 is the master hypoxamir that generally exhibits oncogenic properties in most human solid tumors including bladder cancer (BC). However, it remains unknown about the clinical significance of circulating miR-210 levels in BC. In this study, we found that serum miR-210 was up-regulated in patients with BC, and serum levels of miR-210 increased with advancing stage and grade. Moreover, serum miR-210 expression was found to be significantly reduced in paired post-operative samples and elevated in most patients with relapsed BC. Taken together, our data suggest that serum miR-210 could be a potential noninvasive biomarker for screening, predicting and monitoring BC.

[1]  Hui Liu,et al.  Hypoxia-Inducible MiR-210 Is an Independent Prognostic Factor and Contributes to Metastasis in Colorectal Cancer , 2014, PloS one.

[2]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[3]  Yong Wang,et al.  Comparative mRNA and microRNA Expression Profiling of Three Genitourinary Cancers Reveals Common Hallmarks and Cancer-Specific Molecular Events , 2011, PloS one.

[4]  S. Goodman,et al.  Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.

[5]  D. Spandidos,et al.  Expression of miRNAs involved in angiogenesis, tumor cell proliferation, tumor suppressor inhibition, epithelial-mesenchymal transition and activation of metastasis in bladder cancer. , 2012, The Journal of urology.

[6]  A. Sagalowsky,et al.  Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder , 2006, BJU international.

[7]  S. Vacher,et al.  microRNA expression profile in a large series of bladder tumors: Identification of a 3‐miRNA signature associated with aggressiveness of muscle‐invasive bladder cancer , 2013, International journal of cancer.

[8]  Z. Cai,et al.  Synthetic miRNA-Mowers Targeting miR-183-96-182 Cluster or miR-210 Inhibit Growth and Migration and Induce Apoptosis in Bladder Cancer Cells , 2012, PloS one.

[9]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[10]  R. Rosenfeld.  Patients , 2012, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[11]  Ke Huang,et al.  Hypoxia-induced miR-210 in epithelial ovarian cancer enhances cancer cell viability via promoting proliferation and inhibiting apoptosis. , 2014, International journal of oncology.

[12]  Michael R Hamblin,et al.  CA : A Cancer Journal for Clinicians , 2011 .

[13]  O. Slabý,et al.  Circulating miRNAs as new blood-based biomarkers for solid cancers. , 2013, Future oncology.

[14]  K. Zen,et al.  Circulating MicroRNAs: a novel class of biomarkers to diagnose and monitor human cancers , 2012, Medicinal research reviews.

[15]  P. Whelan.  Bladder cancer--contemporary dilemmas in its management. , 2008, European urology.

[16]  Sota Asaga,et al.  Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. , 2011, Clinical chemistry.

[17]  Edward Messing,et al.  Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. , 2006, JAMA.

[18]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[19]  C. Roehrborn,et al.  Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. , 2003, Urology.

[20]  A. Poprach,et al.  MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma , 2013, Tumor Biology.

[21]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[22]  Yanjie Lu,et al.  MicroRNA miR-133 Represses HERG K+ Channel Expression Contributing to QT Prolongation in Diabetic Hearts* , 2007, Journal of Biological Chemistry.

[23]  M. Babjuk,et al.  Reply to Anna Orsola, Lluís Cecchini and Juan Morote's Letter to the Editor re: Marko Babjuk, Willem Oosterlinck, Richard Sylvester, et al. EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder. Eur Urol 2008;54:303–14 , 2009 .

[24]  Xiaorong Li,et al.  miR-133b regulates the MET proto-oncogene and inhibits the growth of colorectal cancer cells in vitro and in vivo , 2010, Cancer biology & therapy.

[25]  Tian Sheng Chen,et al.  Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs , 2009, Nucleic acids research.

[26]  B. Burwinkel,et al.  Characterization of extracellular circulating microRNA , 2011, Nucleic acids research.

[27]  K. Ohuchida,et al.  MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance , 2009, Molecular Cancer Therapeutics.

[28]  Yanjie Lu,et al.  MicroRNA miR-133 represses HERG K+ channel expression contributing to QT prolongation in diabetic hearts. , 2011, The Journal of Biological Chemistry.

[29]  P Barbry,et al.  miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity , 2011, Cell Death and Differentiation.

[30]  J. R. Wohlgethan,et al.  The clinical and biochemical spectrum of hereditary amyloidosis. , 1988, Seminars in arthritis and rheumatism.

[31]  Hui Liu,et al.  Identification and validation of reference genes for the detection of serum microRNAs by reverse transcription-quantitative polymerase chain reaction in patients with bladder cancer. , 2015, Molecular medicine reports.

[32]  R. Bast,et al.  Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients , 2012, Cancer.

[33]  M. L. Hastings,et al.  Selective Release of MicroRNA Species from Normal and Malignant Mammary Epithelial Cells , 2010, PloS one.

[34]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. , 2008, European urology.

[35]  A. Akobeng,et al.  Understanding diagnostic tests 3: receiver operating characteristic curves , 2007, Acta paediatrica.

[36]  Takahiro Ochiya,et al.  Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis , 2010, Cancer science.

[37]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[38]  Christian Genin,et al.  Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. , 2013, Experimental and molecular pathology.

[39]  Won-Tae Kim,et al.  Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. , 2012, International journal of oncology.

[40]  K. C. Chan,et al.  Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers , 2007, British Journal of Cancer.

[41]  D. Ichikawa,et al.  Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer , 2013, British Journal of Cancer.